| Literature DB >> 35496310 |
Jieqiong Cui1, Meng Li1, Yuanyuan Wei1, Huayan Li1, Xiying He1, Qi Yang1, Zhengkun Li1, Jinfeng Duan1, Zhao Wu1, Qian Chen1, Bojun Chen1, Gang Li1, Xi Ming2, Lei Xiong1, Dongdong Qin1.
Abstract
Mood disorders, also often referred to as affective disorders, are a group of psychiatric illnesses that severely impact mood and its related functions. The high medical expenditures have placed a significant financial burden on patients and their families. Aromatherapy is an alternative and complementary treatment that utilizes essential oils (EOs) or volatile oils (VOs) to achieve major therapeutic goals. In general, EOs are volatile chemicals that enter the body primarily through skin absorption and/or nasal inhalation. In addition, they can work through oral administration. Inhalation aromatherapy has shown unique advantages for treating mood disorders, especially depression, anxiety and mental disorders such as sleep disorder, which have been validated over the last decade through clinical and animal studies. Accumulating evidence has shown that EOs or VOs can bypass the blood-brain barrier to target brain tissue through the nasal-brain pathway. Subsequently, they act on the cerebral cortex, thalamus, and limbic system in the brain to improve symptoms of anxiety, depression and improve sleep quality. Here, we review the natural aromatic plants' volatiles or essential oils used commonly as adjuncts to manage mood disorders and illustrate the mechanisms of inhalation aromatherapy, and mainly summarized the application of transnasal inhalation aromatherapy in depression, anxiety, and sleep disorders. We conclude that aromatherapy does not cause side-effects, which is vastly different from commonly used psychotropic drugs. Inhalation aromatherapy via brain-targeted nasal delivery offers potentially efficacious treatment for mental disorders and merits further study.Entities:
Keywords: anxiety; aromatic herbs; depression; essential oils; inhalation aromatherapy; mood disorders; nasal-brain pathway; sleep disorders
Year: 2022 PMID: 35496310 PMCID: PMC9041268 DOI: 10.3389/fphar.2022.860043
Source DB: PubMed Journal: Front Pharmacol ISSN: 1663-9812 Impact factor: 5.988
FIGURE 1Inhalation of the extracts of aromatic plant via the nose sends signals directly to the olfactory system, where odor molecules target therapeutic drugs to brain tissue via nasal–brain channels. Subsequently, they act on the cerebral cortex, the thalamus, and the limbic system of the brain, and stimulate the brain to produce neurotransmitters to treat the symptoms of anxiety and depression, as well as improve sleep quality (Lv et al., 2013). The aromatic odor molecules are inhaled through the nasal cavity (1) to reach the olfactory epithelium (2) of the nasal mucosa (Schneider et al., 2018). First-order neurons transmit the odor-evoked response to the olfactory bulb (3). In the olfactory bulb, the axons of mitral cells (a) and some tufted cells (b) (secondary neurons) form the olfactory tract (c). The axons of some mitral cells or lateral branches enter the anterior olfactory nucleus (4) and pass to the contralateral olfactory bulb (Cha et al., 2021). Additional secondary neurons enter the olfactory striatum (medial, lateral, and medial) and then project to central olfactory areas, including the olfactory tubercle (5), piriform cortex (6), amygdala (7), and the entorhinal cortex (8). The entorhinal cortex partially transmits to the hippocampus. Eventually, the central olfactory-area signals are transmitted through the thalamus to the orbitofrontal cortex (9) (Lie et al., 2021). An additional olfactory signaling pathway passes directly from the central olfactory area to the prefrontal cortex (10). These impulses induce the release of neurotransmitters such as serotonin or endorphin, which act as a “bridge” between nerves and other bodily systems (Schneider et al., 2018; Smith and Bhatnagar, 2019).
Use of aromatic plants’ volatiles or essential oils to treat neuropsychiatric disorders.
| Scientific name | Main active ingredients | Main indications | Mechanism of action | References |
|---|---|---|---|---|
| Lavender ( | Linalyl acetate, linalool, (E)-β- stilbene, limonene | Anxiety Depression Sleep disorder | ↑: Parasympathetic nervous system |
|
| ↑: Dopamine receptors subtype D3 | ||||
| ↑: Alpha waves in the brain | ||||
| ↓: NMDA receptors | ||||
| ↓: Serotonin transporter (SERT) | ||||
| Roman Chamomile ( | Angelic acid, tiglic acid, α-pinene, and 2-methyl butanoic acid | Anxiety Depression Sleep disorder | ↑: Mitochondrial function |
|
| ↑: Expression of parvalbumin mRNA in hippocampus | ||||
| ↑: Neuroactive ligand- receptor interactions | ||||
| ↑: 5-hydroxytryptamine | ||||
| synapses | ||||
| Bergamot ( | Monoterpenes limonene, monoterpene esters, linalyl acetate, and linalool | Anxiety Depression Sleep disorder | ↑: Synaptic transmission |
|
| ↑: EEG activity | ||||
| ↑: Neuroprotective effects | ||||
| Lemon Balm ( | Citral, citronellal, linalool, geraniol and β-caryophyllene-oxide | Anxiety Depression Fatigue | ↑: Dopamine |
|
| ↑: Serotonin | ||||
| Saint John’s wort ( | Germacrene D, ( | Anxiety Depression Sleep disorder | ↑: Serotonergic system |
|
| ↓: Monoamine neurotransmitters | ||||
| Rhodiola rosea L. ( | Cinnamyl alcohol glycosides such as rosin, rosavin, and the phenylethanoid compound salidroside with its aglycone tyrosol | Anxiety Depression Sleep disorder Fatigue | ↑: Neurotransmitters |
|
| ↑: BDNF/TrkB signaling pathway | ||||
| ↓: Anti-inflammatory action | ||||
| ↓: Glucocorticoid receptor | ||||
| ↓: Activity of HPA axis | ||||
| Cang-ai volatile oil | Eugenol, 1,8-cineole, patchouli alcohol, acetyl eugenol, linalool, linalyl acetate | Depression | ↑: Dopamine |
|
| ↑: 5-hydroxytryptamine |
↑, enhance, activate or increase; ↓, weaken, inactivate or decrease.